Pei-Pei Qiao1,2, Kai-Sai Tian1,2, Li-Tao Han2,3, Ben Ma2,3, Cen-Kai Shen2,3, Run-Yu Zhao1, Yi Zhang4, Wen-Jun Wei5,6, Xiao-Ping Chen7. 1. Ningxia Medical University, Yinchuan, 750004, China. 2. Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. 3. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. 4. Department of Otorhinolaryngology Head and Neck Surgery, Shanghai Pudong New Area Gongli Hospital, Shanghai, 200135, China. 5. Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. kakarwen@163.com. 6. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. kakarwen@163.com. 7. Department of Otorhinolaryngology Head and Neck Surgery, Shanghai Pudong New Area Gongli Hospital, Shanghai, 200135, China. chen_xp2000@163.com.
Abstract
BACKGROUND: Mutations in DNA mismatch repair (MMR) genes associated with thyroid carcinoma (TC) have rarely been reported, especially in East Asian populations. METHODS: We examined tumor tissue from a cohort of 241 patients diagnosed with TC between 2008 and 2020. MMR proteins were detected using tissue microarray-based immunohistochemistry in order to identify MMR-protein-deficient (MMR-D) and MMR-protein-intact (MMR-I) tumors. We retrospectively summarized the clinicopathologic characteristics of patients with MMR-D TC, measured the expression of PD-L1, and recorded overall survival (OS) and other clinical outcomes. RESULTS: In our cohort, there were 18 (7.5%) MMR-D (MLH1, MSH2, MSH6, and PMS2) patients, including 12 with papillary TC (PTC) (6.7%), 2 with poorly differentiated TC (PDTC) (4.7%), and 4 with anaplastic TC (ATC) (22.2%). Half of them (9/18) showed a specific deletion in MSH6, and 6 of them also carried variants in the MSH6 and PMS2 gene. Survival was significantly better in patients with MMR-D ATC than in those with MMR-I tumors (p = 0.033). Four of the 18 MMR-D patients (22%) were found to be PD-L1 positive. Their OS was much shorter than that of PD-L1-negative patients. CONCLUSIONS: MMR-D and PD-L1 positivity appear to be associated with clinicopathological characteristics and prognosis in TC. The results indicate that MMR status may have important prognostic significance in TC. Therefore, immune checkpoint inhibitors that target the PD-1/PD-L1 pathway may be a treatment option for TCs.
BACKGROUND: Mutations in DNA mismatch repair (MMR) genes associated with thyroid carcinoma (TC) have rarely been reported, especially in East Asian populations. METHODS: We examined tumor tissue from a cohort of 241 patients diagnosed with TC between 2008 and 2020. MMR proteins were detected using tissue microarray-based immunohistochemistry in order to identify MMR-protein-deficient (MMR-D) and MMR-protein-intact (MMR-I) tumors. We retrospectively summarized the clinicopathologic characteristics of patients with MMR-D TC, measured the expression of PD-L1, and recorded overall survival (OS) and other clinical outcomes. RESULTS: In our cohort, there were 18 (7.5%) MMR-D (MLH1, MSH2, MSH6, and PMS2) patients, including 12 with papillary TC (PTC) (6.7%), 2 with poorly differentiated TC (PDTC) (4.7%), and 4 with anaplastic TC (ATC) (22.2%). Half of them (9/18) showed a specific deletion in MSH6, and 6 of them also carried variants in the MSH6 and PMS2 gene. Survival was significantly better in patients with MMR-D ATC than in those with MMR-I tumors (p = 0.033). Four of the 18 MMR-D patients (22%) were found to be PD-L1 positive. Their OS was much shorter than that of PD-L1-negative patients. CONCLUSIONS: MMR-D and PD-L1 positivity appear to be associated with clinicopathological characteristics and prognosis in TC. The results indicate that MMR status may have important prognostic significance in TC. Therefore, immune checkpoint inhibitors that target the PD-1/PD-L1 pathway may be a treatment option for TCs.
Authors: Heather Hampel; Wendy L Frankel; Edward Martin; Mark Arnold; Karamjit Khanduja; Philip Kuebler; Mark Clendenning; Kaisa Sotamaa; Thomas Prior; Judith A Westman; Jenny Panescu; Dan Fix; Janet Lockman; Jennifer LaJeunesse; Ilene Comeras; Albert de la Chapelle Journal: J Clin Oncol Date: 2008-09-22 Impact factor: 44.544
Authors: Michael J Overman; Ray McDermott; Joseph L Leach; Sara Lonardi; Heinz-Josef Lenz; Michael A Morse; Jayesh Desai; Andrew Hill; Michael Axelson; Rebecca A Moss; Monica V Goldberg; Z Alexander Cao; Jean-Marie Ledeine; Gregory A Maglinte; Scott Kopetz; Thierry André Journal: Lancet Oncol Date: 2017-07-19 Impact factor: 41.316
Authors: Sarika N Rao; Mark Zafereo; Ramona Dadu; Naifa L Busaidy; Kenneth Hess; Gilbert J Cote; Michelle D Williams; William N William; Vlad Sandulache; Neil Gross; G Brandon Gunn; Charles Lu; Renata Ferrarotto; Stephen Y Lai; Maria E Cabanillas Journal: Thyroid Date: 2017-02-16 Impact factor: 6.568
Authors: Heather Hampel; Wendy L Frankel; Edward Martin; Mark Arnold; Karamjit Khanduja; Philip Kuebler; Hidewaki Nakagawa; Kaisa Sotamaa; Thomas W Prior; Judith Westman; Jenny Panescu; Dan Fix; Janet Lockman; Ilene Comeras; Albert de la Chapelle Journal: N Engl J Med Date: 2005-05-05 Impact factor: 91.245
Authors: C Luchini; F Bibeau; M J L Ligtenberg; N Singh; A Nottegar; T Bosse; R Miller; N Riaz; J-Y Douillard; F Andre; A Scarpa Journal: Ann Oncol Date: 2019-08-01 Impact factor: 32.976
Authors: Alicia Latham; Preethi Srinivasan; Yelena Kemel; Jinru Shia; Chaitanya Bandlamudi; Diana Mandelker; Sumit Middha; Jaclyn Hechtman; Ahmet Zehir; Marianne Dubard-Gault; Christina Tran; Carolyn Stewart; Margaret Sheehan; Alexander Penson; Deborah DeLair; Rona Yaeger; Joseph Vijai; Semanti Mukherjee; Jesse Galle; Mark A Dickson; Yelena Janjigian; Eileen M O'Reilly; Neil Segal; Leonard B Saltz; Diane Reidy-Lagunes; Anna M Varghese; Dean Bajorin; Maria I Carlo; Karen Cadoo; Michael F Walsh; Martin Weiser; Julio Garcia Aguilar; David S Klimstra; Luis A Diaz; Jose Baselga; Liying Zhang; Marc Ladanyi; David M Hyman; David B Solit; Mark E Robson; Barry S Taylor; Kenneth Offit; Michael F Berger; Zsofia K Stadler Journal: J Clin Oncol Date: 2018-10-30 Impact factor: 50.717